TheraCell was issued U.S. Patent No. 9,636,436, “Compositions of and Methods for Cancellous Bone Matrix,” addressing its enhanced cancellous demineralized bone technology, ECS™.
ECS is a minimally-manipulated tissue product designed to combine the osteoinductivity of demineralized cortical bone powder with the osteoconductivity of demineralized cancellous bone. This patent extends TheraCell’s osteobiologic patent portfolio that also includes protection for Demineralized Bone Fiber.
Sources: TheraCell, Inc.; ORTHOWORLD Inc.
TheraCell was issued U.S. Patent No. 9,636,436, "Compositions of and Methods for Cancellous Bone Matrix," addressing its enhanced cancellous demineralized bone technology, ECS™.
ECS is a minimally-manipulated tissue product designed to combine the...
TheraCell was issued U.S. Patent No. 9,636,436, “Compositions of and Methods for Cancellous Bone Matrix,” addressing its enhanced cancellous demineralized bone technology, ECS™.
ECS is a minimally-manipulated tissue product designed to combine the osteoinductivity of demineralized cortical bone powder with the osteoconductivity of demineralized cancellous bone. This patent extends TheraCell’s osteobiologic patent portfolio that also includes protection for Demineralized Bone Fiber.
Sources: TheraCell, Inc.; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
